InvestorsHub Logo
Followers 58
Posts 10044
Boards Moderated 1
Alias Born 09/21/2016

Re: None

Friday, 12/28/2018 3:08:41 PM

Friday, December 28, 2018 3:08:41 PM

Post# of 458507
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220180360796%22.PGNR.&OS=DN/20180360796&RS=DN/20180360796

IMO, this latest patent is for the process of evaluating and dosing AD patients in the trial using A2-73 (and other) treatments. The AI tool in use by Cognision/w/Anavex (IMO) will be used to verify the effectiveness of dosing at different levels and varying intervals. The AI w/biomarker information will replace the trial and error, time based trial methods.

This is not the old put a note in a bottle and wait method. IMO, massive breakthrough, unless I have misread the whole thing.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News